{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T02:02:08Z","timestamp":1768269728908,"version":"3.49.0"},"reference-count":122,"publisher":"National Institute for Health and Care Research","issue":"37","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["11\/58\/15"],"award-info":[{"award-number":["11\/58\/15"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n Despite widespread use of therapies such as inhaled corticosteroids (ICSs), people with chronic obstructive pulmonary disease (COPD) continue to suffer, have reduced life expectancy and utilise considerable NHS resources. Laboratory investigations have demonstrated that at low plasma concentrations (1\u20135\u2009mg\/l) theophylline markedly enhances the anti-inflammatory effects of corticosteroids in COPD.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine the clinical effectiveness and cost-effectiveness of adding low-dose theophylline to a drug regimen containing ICSs in people with COPD at high risk of exacerbation.<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n A multicentre, pragmatic, double-blind, randomised, placebo-controlled clinical trial.<\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n The trial was conducted in 121 UK primary and secondary care sites.<\/jats:p>\n <\/jats:sec>\n \n Participants<\/jats:title>\n People with COPD [i.e. who have a forced expiratory volume in 1 second (FEV1<\/jats:sub>)\/forced vital capacity (FVC) of <\u20090.7] currently on a drug regimen including ICSs with a history of two or more exacerbations treated with antibiotics and\/or oral corticosteroids (OCSs) in the previous year.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants were randomised (1\u2009:\u20091) to receive either low-dose theophylline or placebo for 1 year. The dose of theophylline (200\u2009mg once or twice a day) was determined by ideal body weight and smoking status.<\/jats:p>\n <\/jats:sec>\n \n Primary outcome<\/jats:title>\n The number of participant-reported exacerbations in the 1-year treatment period that were treated with antibiotics and\/or OCSs.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 1578 people were randomised (60% from primary care): 791 to theophylline and 787 to placebo. There were 11 post-randomisation exclusions. Trial medication was prescribed to 1567 participants: 788 in the theophylline arm and 779 in the placebo arm. Participants in the trial arms were well balanced in terms of characteristics. The mean age was 68.4 [standard deviation (SD) 8.4] years, 54% were male, 32% smoked and mean FEV1<\/jats:sub> was 51.7% (SD 20.0%) predicted. Primary outcome data were available for 98% of participants: 772 in the theophylline arm and 764 in the placebo arm. There were 1489 person-years of follow-up data. The mean number of exacerbations was 2.24 (SD 1.99) for participants allocated to theophylline and 2.23 (SD 1.97) for participants allocated to placebo [adjusted incidence rate ratio (IRR) 0.99, 95% confidence interval (CI) 0.91 to 1.08]. Low-dose theophylline had no significant effects on lung function (i.e. FEV1<\/jats:sub>), incidence of pneumonia, mortality, breathlessness or measures of quality of life or disease impact. Hospital admissions due to COPD exacerbation were less frequent with low-dose theophylline (adjusted IRR 0.72, 95% CI 0.55 to 0.94). However, 39 of the 51 excess hospital admissions in the placebo group were accounted for by 10 participants having three or more exacerbations. There were no differences in the reporting of theophylline side effects between the theophylline and placebo arms.<\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n A higher than expected percentage of participants (26%) ceased trial medication; this was balanced between the theophylline and placebo arms and mitigated by over-recruitment (n<\/jats:italic>\u2009=\u2009154 additional participants were recruited) and the high rate of follow-up. The limitation of not using documented exacerbations is addressed by evidence that patient recall is highly reliable and the results of a small within-trial validation study.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n For people with COPD at high risk of exacerbation, the addition of low-dose oral theophylline to a drug regimen that includes ICSs confers no overall clinical or health economic benefit. This result was evident from the intention-to-treat and per-protocol analyses.<\/jats:p>\n <\/jats:sec>\n \n Future work<\/jats:title>\n To promote consideration of the findings of this trial in national and international COPD guidelines.<\/jats:p>\n <\/jats:sec>\n \n Trial registration<\/jats:title>\n Current Controlled Trials ISRCTN27066620.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment<\/jats:italic>; Vol. 23, No. 37. See the NIHR Journals Library website for further project information.<\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/hta23370","type":"journal-article","created":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T14:56:37Z","timestamp":1564066597000},"page":"1-146","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT"],"prefix":"10.3310","volume":"23","clinical-trial-number":[{"clinical-trial-number":"isrctn27066620","registry":"10.18810\/isrctn","type":"results"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0024-4887","authenticated-orcid":true,"given":"Graham","family":"Devereux","sequence":"first","affiliation":[{"name":"Respiratory Medicine, Aberdeen Royal Infirmary, University of Aberdeen, Aberdeen, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7883-0608","authenticated-orcid":true,"given":"Seonaidh","family":"Cotton","sequence":"additional","affiliation":[{"name":"Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5363-8188","authenticated-orcid":true,"given":"Shona","family":"Fielding","sequence":"additional","affiliation":[{"name":"Medical Statistics Team, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2918-8820","authenticated-orcid":true,"given":"Nicola","family":"McMeekin","sequence":"additional","affiliation":[{"name":"Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5122-4018","authenticated-orcid":true,"given":"Peter J","family":"Barnes","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Briggs","sequence":"additional","affiliation":[{"name":"Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Burns","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Royal Victoria Infirmary, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8007-949X","authenticated-orcid":true,"given":"Rekha","family":"Chaudhuri","sequence":"additional","affiliation":[{"name":"Gartnavel General Hospital, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1528-2146","authenticated-orcid":true,"given":"Henry","family":"Chrystyn","sequence":"additional","affiliation":[{"name":"Inhalation Consultancy Ltd, Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Davies","sequence":"additional","affiliation":[{"name":"Aintree Chest Centre, University Hospital Aintree, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8566-0344","authenticated-orcid":true,"given":"Anthony De","family":"Soyza","sequence":"additional","affiliation":[{"name":"Medical School, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Gompertz","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Hospital Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6809-6964","authenticated-orcid":true,"given":"John","family":"Haughney","sequence":"additional","affiliation":[{"name":"Gartnavel General Hospital, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Innes","sequence":"additional","affiliation":[{"name":"Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5479-6820","authenticated-orcid":true,"given":"Joanna","family":"Kaniewska","sequence":"additional","affiliation":[{"name":"Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Lee","sequence":"additional","affiliation":[{"name":"Medical Statistics Team, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6135-9610","authenticated-orcid":true,"given":"Alyn","family":"Morice","sequence":"additional","affiliation":[{"name":"Cardiovascular and Respiratory Studies, Castle Hill Hospital, Cottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9823-9252","authenticated-orcid":true,"given":"John","family":"Norrie","sequence":"additional","affiliation":[{"name":"Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Hospital Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5514-4867","authenticated-orcid":true,"given":"Andrew","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Norwich Medical School, University of East Anglia, Norwich, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-9992","authenticated-orcid":true,"given":"David","family":"Price","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, Aberdeen Royal Infirmary, University of Aberdeen, Aberdeen, UK"},{"name":"Academic Primary Care, University of Aberdeen, Aberdeen, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6221","published-online":{"date-parts":[[2019,7]]},"reference":[{"key":"key20190724132637972_ref1-bib1","volume-title":"Global Strategy for the Diagnosis, Management and Prevention of COPD","author":"Global Initiative for Chronic Obstructive Lung Disease (GOLD)","year":"2017"},{"key":"key20190724132637972_ref1-bib2","volume-title":"Chronic Obstructive Pulmonary Disease (COPD) Statistics","author":"British Lung Foundation"},{"key":"key20190724132637972_ref1-bib3","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(07)61377-4","article-title":"International variation in the prevalence of COPD (the BOLD study): a population-based prevalence study","volume":"370","author":"Buist","year":"2007","journal-title":"Lancet"},{"key":"key20190724132637972_ref1-bib4","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1183\/09031936.01.17510240","article-title":"Urban air pollution and chronic obstructive pulmonary disease: a review","volume":"17","author":"Sunyer","year":"2001","journal-title":"Eur Respir J"},{"key":"key20190724132637972_ref1-bib5","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1164\/rccm.167.5.787","article-title":"American Thoracic Society statement: occupational contribution to the burden of airway disease","volume":"167","author":"Balmes","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"key20190724132637972_ref1-bib6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3109\/15412555.2011.648030","article-title":"Chronic obstructive pulmonary disease and socioeconomic status: a systematic review","volume":"9","author":"Gershon","year":"2012","journal-title":"COPD"},{"key":"key20190724132637972_ref1-bib7","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1183\/09031936.00012408","article-title":"Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD","volume":"32","author":"Mannino","year":"2008","journal-title":"Eur Respir J"},{"key":"key20190724132637972_ref1-bib8","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1378\/chest.128.4.2005","article-title":"Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001","volume":"128","author":"Holguin","year":"2005","journal-title":"Chest"},{"key":"key20190724132637972_ref1-bib9","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1183\/09031936.97.10122794","article-title":"Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease","volume":"10","author":"Antonelli Incalzi","year":"1997","journal-title":"Eur Respir J"},{"key":"key20190724132637972_ref1-bib10","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1093\/eurheartj\/ehi291","article-title":"Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease","volume":"26","author":"Rutten","year":"2005","journal-title":"Eur Heart J"},{"key":"key20190724132637972_ref1-bib11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1183\/09031936.00044411","article-title":"Unrecognised ventricular dysfunction in COPD","volume":"39","author":"Macchia","year":"2012","journal-title":"Eur Respir J"},{"key":"key20190724132637972_ref1-bib12","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.2337\/diacare.27.10.2478","article-title":"Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women","volume":"27","author":"Rana","year":"2004","journal-title":"Diabetes Care"},{"key":"key20190724132637972_ref1-bib13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S0002-9343(02)01297-4","article-title":"The risk of osteoporosis in Caucasian men and women with obstructive airways disease","volume":"114","author":"Sin","year":"2003","journal-title":"Am J Med"},{"key":"key20190724132637972_ref1-bib14","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/j.rmed.2006.01.026","article-title":"Anxiety and depression in COPD patients: the roles of gender and disease severity","volume":"100","author":"Di Marco","year":"2006","journal-title":"Respir Med"},{"key":"key20190724132637972_ref1-bib15","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1001\/archinte.163.12.1475","article-title":"Low lung function and incident lung cancer in the United States: data from the First National Health and Nutrition Examination Survey follow-up","volume":"163","author":"Mannino","year":"2003","journal-title":"Arch Intern Med"},{"key":"key20190724132637972_ref1-bib16","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1136\/thorax.57.10.847","article-title":"Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease","volume":"57","author":"Donaldson","year":"2002","journal-title":"Thorax"},{"key":"key20190724132637972_ref1-bib17","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1164\/rccm.200408-1054OC","article-title":"Exacerbations and time spent outdoors in chronic obstructive pulmonary disease","volume":"171","author":"Donaldson","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"5 Pt 1","key":"key20190724132637972_ref1-bib18","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1164\/ajrccm.157.5.9709032","article-title":"Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease","volume":"157","author":"Seemungal","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"key20190724132637972_ref1-bib19","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1136\/thx.2005.040527","article-title":"Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease","volume":"60","author":"Soler-Catalu\u00f1a","year":"2005","journal-title":"Thorax"},{"key":"key20190724132637972_ref1-bib20","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1183\/09031936.00124811","article-title":"Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD","volume":"39","author":"McAllister","year":"2012","journal-title":"Eur Respir J"},{"key":"key20190724132637972_ref1-bib21","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","article-title":"Susceptibility to exacerbation in chronic obstructive pulmonary disease","volume":"363","author":"Hurst","year":"2010","journal-title":"N Engl J Med"},{"key":"key20190724132637972_ref1-bib22","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.2147\/COPD.S94259","article-title":"Predicting frequent COPD exacerbations using primary care data","volume":"10","author":"Kerkhof","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"key20190724132637972_ref1-bib23","unstructured":"Department of Health and Social Care (DHSC). An Outcomes Strategy for COPD and Asthma. London: DHSC; 2012. URL: www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/216531\/dh_134001.pdf (accessed March 2018)."},{"key":"key20190724132637972_ref1-bib24","unstructured":"National Institute for Health and Care Excellence (NICE). Chronic Obstructive Pulmonary Disease in Over 16s: Diagnosis and Management. London: NICE; 2010. URL: www.nice.org.uk\/guidance\/cg101 (accessed March 2018)."},{"key":"key20190724132637972_ref1-bib25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1477-7525-3-56","article-title":"Health-related quality of life is related to COPD disease severity","volume":"3","author":"St\u00e5hl","year":"2005","journal-title":"Health Qual Life Outcomes"},{"key":"key20190724132637972_ref1-bib26","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.7326\/0003-4819-127-12-199712150-00003","article-title":"Chronic obstructive pulmonary disease stage and health-related quality of life. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group","volume":"127","author":"Ferrer","year":"1997","journal-title":"Ann Intern Med"},{"key":"key20190724132637972_ref1-bib27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0954-6111(03)80027-6","article-title":"The burden of COPD in the UK: results from the Confronting COPD survey","volume":"97","author":"Britton","year":"2003","journal-title":"Respir Med"},{"key":"key20190724132637972_ref1-bib28","unstructured":"NHS Digital. Hospital Episode Statistics. Leeds: NHS Digital; 2016. URL: http:\/\/content.digital.nhs.uk\/searchcatalogue?topics=2%2fHospital+care%2fAdmissions+and+attendances%2fInpatients&sort=Relevance&size=10&page=1#top (accessed March 2018)."},{"key":"key20190724132637972_ref1-bib29","doi-asserted-by":"publisher","first-page":"16061","DOI":"10.1038\/npjpcrm.2016.61","article-title":"First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis","volume":"26","author":"Price","year":"2016","journal-title":"NPJ Prim Care Respir Med"},{"key":"key20190724132637972_ref1-bib30","doi-asserted-by":"publisher","first-page":"16002","DOI":"10.1038\/npjpcrm.2016.2","article-title":"Changes in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: in UK primary care: a real-world study","volume":"26","author":"Gruffydd-Jones","year":"2016","journal-title":"NPJ Prim Care Respir Med"},{"key":"key20190724132637972_ref1-bib31","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N Engl J Med"},{"key":"key20190724132637972_ref1-bib32","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S0140-6736(04)15650-X","article-title":"Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase","volume":"363","author":"Barnes","year":"2004","journal-title":"Lancet"},{"key":"key20190724132637972_ref1-bib33","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4104\/pcrj.2012.00092","article-title":"Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD","volume":"22","author":"Price","year":"2013","journal-title":"Prim Care Respir J"},{"key":"key20190724132637972_ref1-bib34","doi-asserted-by":"publisher","first-page":"e0162903","DOI":"10.1371\/journal.pone.0162903","article-title":"Metabolic effects associated with ICS in patients with COPD and comorbid type 2 diabetes: a historical matched cohort study","volume":"11","author":"Price","year":"2016","journal-title":"PLOS ONE"},{"key":"key20190724132637972_ref1-bib35","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1164\/ajrccm.160.5.9811058","article-title":"Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease","volume":"160","author":"Culpitt","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"key20190724132637972_ref1-bib36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1164\/rccm.200204-298OC","article-title":"Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease","volume":"167","author":"Culpitt","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"key20190724132637972_ref1-bib37","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1164\/rccm.2105025","article-title":"The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study","volume":"165","author":"Hattotuwa","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"key20190724132637972_ref1-bib38","doi-asserted-by":"publisher","first-page":"6891","DOI":"10.1128\/MCB.20.18.6891-6903.2000","article-title":"Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12","volume":"20","author":"Ito","year":"2000","journal-title":"Mol Cell Biol"},{"key":"key20190724132637972_ref1-bib39","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1056\/NEJMoa041892","article-title":"Decreased histone deacetylase activity in chronic obstructive pulmonary disease","volume":"352","author":"Ito","year":"2005","journal-title":"N Engl J Med"},{"key":"key20190724132637972_ref1-bib40","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1084\/jem.20050466","article-title":"Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression","volume":"203","author":"Ito","year":"2006","journal-title":"J Exp Med"},{"key":"key20190724132637972_ref1-bib41","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1513\/pats.200907-071DP","article-title":"Targeting the epigenome in the treatment of asthma and chronic obstructive pulmonary disease","volume":"6","author":"Barnes","year":"2009","journal-title":"Proc Am Thorac Soc"},{"key":"key20190724132637972_ref1-bib42","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1164\/rccm.200810-1570OC","article-title":"Inhibition of PI3Kdelta restores glucocorticoid function in smoking-induced airway inflammation in mice","volume":"179","author":"Marwick","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"key20190724132637972_ref1-bib43","doi-asserted-by":"publisher","first-page":"8921","DOI":"10.1073\/pnas.132556899","article-title":"A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression","volume":"99","author":"Ito","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20190724132637972_ref1-bib44","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1084\/jem.20040416","article-title":"Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages","volume":"200","author":"Cosio","year":"2004","journal-title":"J Exp Med"},{"key":"key20190724132637972_ref1-bib45","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1139\/y2012-079","article-title":"Low-dose theophylline restores corticosteroid responsiveness in rats with smoke-induced airway inflammation","volume":"90","author":"Sun","year":"2012","journal-title":"Can J Physiol Pharmacol"},{"key":"key20190724132637972_ref1-bib46","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1164\/rccm.200906-0937OC","article-title":"Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease","volume":"182","author":"To","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"key20190724132637972_ref1-bib47","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.pupt.2012.04.001","article-title":"Long-acting \u03b22 agonists and corticosteroids restore the reduction of histone deacetylase activity and inhibit H2O2-induced mediator release from alveolar macrophages","volume":"25","author":"Perng","year":"2012","journal-title":"Pulm Pharmacol Ther"},{"key":"key20190724132637972_ref1-bib48","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1136\/thx.2008.103432","article-title":"Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD","volume":"64","author":"Cosio","year":"2009","journal-title":"Thorax"},{"key":"key20190724132637972_ref1-bib49","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1378\/chest.09-2363","article-title":"Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD","volume":"137","author":"Ford","year":"2010","journal-title":"Chest"},{"key":"key20190724132637972_ref1-bib50","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1365-2125.2007.02977.x","article-title":"Effect of theophylline on the rate of moderate to severe exacerbations among patients with chronic obstructive pulmonary disease","volume":"65","author":"Cyr","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"key20190724132637972_ref1-bib51","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3238\/arztebl.2014.0293","article-title":"The effects of theophylline on hospital admissions and exacerbations in COPD patients: audit data from the Bavarian disease management program","volume":"111","author":"Fexer","year":"2014","journal-title":"Dtsch Arztebl Int"},{"key":"key20190724132637972_ref1-bib52","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.chest.2016.04.011","article-title":"Oral low-dose theophylline on top of inhaled fluticasone-salmeterol does not reduce exacerbations in patients with severe COPD: a pilot clinical trial","volume":"150","author":"Cos\u00edo","year":"2016","journal-title":"Chest"},{"key":"key20190724132637972_ref1-bib53","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1136\/thx.48.3.227","article-title":"Value of theophylline treatment in patients handicapped by chronic obstructive lung disease","volume":"48","author":"McKay","year":"1993","journal-title":"Thorax"},{"key":"key20190724132637972_ref1-bib54","volume-title":"Uniphyllin Continus Tablets","author":"Napp Pharmaceuticals Ltd","year":"2014"},{"key":"key20190724132637972_ref1-bib55","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s13063-015-0782-2","article-title":"Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial","volume":"16","author":"Devereux","year":"2015","journal-title":"Trials"},{"key":"key20190724132637972_ref1-bib56","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1517\/14656566.7.6.639","article-title":"Drug interactions during therapy with three major groups of antimicrobial agents","volume":"7","author":"Shakeri-Nejad","year":"2006","journal-title":"Expert Opin Pharmacother"},{"issue":"5 Pt 1","key":"key20190724132637972_ref1-bib57","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/cpt1976195part1546","article-title":"Effect of smoking on theophylline disposition","volume":"19","author":"Hunt","year":"1976","journal-title":"Clin Pharmacol Ther"},{"key":"key20190724132637972_ref1-bib58","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1164\/arrd.1977.116.1.17","article-title":"The influence of cigarette smoking and sex on theophylline disposition","volume":"116","author":"Powell","year":"1977","journal-title":"Am Rev Respir Dis"},{"key":"key20190724132637972_ref1-bib59","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1164\/arrd.1978.118.2.229","article-title":"Theophylline disposition in acutely ill hospitalized patients. The effect of smoking, heart failure, severe airway obstruction, and pneumonia","volume":"118","author":"Powell","year":"1978","journal-title":"Am Rev Respir Dis"},{"key":"key20190724132637972_ref1-bib60","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/cpt1978244406","article-title":"Enhanced biotransformation of theophylline in marihuana and tobacco smokers","volume":"24","author":"Jusko","year":"1978","journal-title":"Clin Pharmacol Ther"},{"key":"key20190724132637972_ref1-bib61","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/BF01066061","article-title":"Role of tobacco smoking in pharmacokinetics","volume":"6","author":"Jusko","year":"1978","journal-title":"J Pharmacokinet Biopharm"},{"key":"key20190724132637972_ref1-bib62","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1164\/arrd.1978.118.1.97","article-title":"Disposition of theophylline after a single intravenous infusion of aminophylline","volume":"118","author":"Hendeles","year":"1978","journal-title":"Am Rev Respir Dis"},{"key":"key20190724132637972_ref1-bib63","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1365-2125.1989.tb05353.x","article-title":"Bayesian derived predictions for twice daily theophylline under outpatient conditions and an assessment of optimal sampling times","volume":"27","author":"Chrystyn","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"key20190724132637972_ref1-bib64","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1136\/bmj.297.6662.1506","article-title":"Dose response relation to oral theophylline in severe chronic obstructive airways disease","volume":"297","author":"Chrystyn","year":"1988","journal-title":"BMJ"},{"key":"key20190724132637972_ref1-bib65","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/00007691-198803000-00011","article-title":"The accuracy and stability of Bayesian theophylline predictions","volume":"10","author":"Chrystyn","year":"1988","journal-title":"Ther Drug Monit"},{"key":"key20190724132637972_ref1-bib66","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1365-2125.1987.tb03173.x","article-title":"The accuracy of a pharmacokinetic theophylline predictor using once daily dosing","volume":"24","author":"Chrystyn","year":"1987","journal-title":"Br J Clin Pharmacol"},{"key":"key20190724132637972_ref1-bib67","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1177\/0115426506021003312","article-title":"Comparison of ideal body weight equations and published height-weight tables with body mass index tables for healthy adults in the United States","volume":"21","author":"Shah","year":"2006","journal-title":"Nutr Clin Pract"},{"key":"key20190724132637972_ref1-bib68","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1183\/09031936.04.00014304","article-title":"Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper","volume":"23","author":"Celli","year":"2004","journal-title":"Eur Respir J"},{"key":"key20190724132637972_ref1-bib69","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol \u2013 a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol Group","year":"1990","journal-title":"Health Policy"},{"key":"key20190724132637972_ref1-bib70","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","article-title":"EuroQol: the current state of play","volume":"37","author":"Brooks","year":"1996","journal-title":"Health Policy"},{"key":"key20190724132637972_ref1-bib71","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0168-8510(96)00853-6","article-title":"Modelling valuations for health states: the effect of duration","volume":"38","author":"Dolan","year":"1996","journal-title":"Health Policy"},{"key":"key20190724132637972_ref1-bib72","volume-title":"COPD Assessment Test","author":"CAT Governance Board","year":"2016"},{"key":"key20190724132637972_ref1-bib73","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1136\/thx.2010.156372","article-title":"The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study","volume":"66","author":"Dodd","year":"2011","journal-title":"Thorax"},{"key":"key20190724132637972_ref1-bib74","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1183\/09031936.00102509","article-title":"Development and first validation of the COPD Assessment Test","volume":"34","author":"Jones","year":"2009","journal-title":"Eur Respir J"},{"key":"key20190724132637972_ref1-bib75","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1136\/bmj.2.5213.1665","article-title":"Standardised questionnaire on respiratory symptoms: a statement prepared and approved by the MRC Committee on the Aetiology of Chronic Bronchitis","volume":"2","author":"Fletcher","year":"1960","journal-title":"Br Med J"},{"key":"key20190724132637972_ref1-bib76","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1136\/thx.54.7.581","article-title":"Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease","volume":"54","author":"Bestall","year":"1999","journal-title":"Thorax"},{"key":"key20190724132637972_ref1-bib77","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00408-010-9272-1","article-title":"Cough hypersensitivity syndrome: a distinct clinical entity","volume":"189","author":"Morice","year":"2011","journal-title":"Lung"},{"key":"key20190724132637972_ref1-bib78","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"key":"key20190724132637972_ref1-bib79","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1183\/09041950.005s1693","article-title":"Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the European Respiratory Society","volume":"16","author":"Quanjer","year":"1993","journal-title":"Eur Respir J Suppl"},{"key":"key20190724132637972_ref1-bib80","doi-asserted-by":"publisher","first-page":"s75","DOI":"10.1192\/bjp.190.5.s75","article-title":"Collecting service use data for economic evaluation in DSPD populations: development of the secure facilities service use schedule","volume":"49","author":"Barrett","year":"2007","journal-title":"Br J Psychiatry Suppl"},{"key":"key20190724132637972_ref1-bib81","unstructured":"NHS Health Research Authority. Safety and Progress Reports (CTIMPs). London: NHS Health Research Authority; 2007. URL: www.hra.nhs.uk\/approvals-amendments\/managing-your-approval\/safety-reporting\/ (accessed March 2018)."},{"key":"key20190724132637972_ref1-bib82","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/S0149-2918(99)80026-5","article-title":"Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice","volume":"21","author":"Farmer","year":"1999","journal-title":"Clin Ther"},{"key":"key20190724132637972_ref1-bib83","doi-asserted-by":"publisher","first-page":"CD003902","DOI":"10.1002\/14651858.CD003902","article-title":"Oral theophylline for chronic obstructive pulmonary disease","volume":"4","author":"Ram","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"key20190724132637972_ref1-bib84","doi-asserted-by":"publisher","first-page":"s28","DOI":"10.1192\/bjp.177.39.s28","article-title":"Client Socio-Demographic and Service Receipt Inventory \u2013 European Version: development of an instrument for international research. EPSILON Study 5. European Psychiatric Services: Inputs Linked to Outcome Domains and Needs","volume":"39","author":"Chisholm","year":"2000","journal-title":"Br J Psychiatry Suppl"},{"key":"key20190724132637972_ref1-bib85","volume-title":"Unit Costs of Health and Social Care 2016","author":"Curtis","year":"2016"},{"key":"key20190724132637972_ref1-bib86","unstructured":"Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press. URL: www.medicinescomplete.com (accessed March 2018)."},{"key":"key20190724132637972_ref1-bib87","unstructured":"Department of Health and Social Care (DHSC). NHS Reference Costs 2015 to 2016. GOV.UK. London: DHSC; 2018. URL: www.gov.uk\/government\/publications\/nhs-reference-costs-2015-to-2016 (accessed March 2018)."},{"key":"key20190724132637972_ref1-bib88","unstructured":"Information Services Division Scotland. ISD Scotland Costs, Finance. Edinburgh: ISD Scotland; 2017. URL: www.isdscotland.org\/Health-Topics\/Finance\/Costs\/ (accessed March 2018)."},{"key":"key20190724132637972_ref1-bib89","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1524-4733.2005.03086.x","article-title":"Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries","volume":"8","author":"Oostenbrink","year":"2005","journal-title":"Value Health"},{"key":"key20190724132637972_ref1-bib90","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/003693300404900208","article-title":"What does GP out of hours care cost? An analysis of different models of out of hours care in Scotland","volume":"49","author":"Scott","year":"2004","journal-title":"Scott Med J"},{"key":"key20190724132637972_ref1-bib91","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/hec.944","article-title":"Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility","volume":"14","author":"Manca","year":"2005","journal-title":"Health Econ"},{"key":"key20190724132637972_ref1-bib92","volume-title":"Unit Costs of Health and Social Care 2010","author":"Curtis","year":"2010"},{"key":"key20190724132637972_ref1-bib93","volume-title":"Guide to the Methods of Technology Appraisal","author":"National Institute for Health and Care Excellence (NICE)","year":"2013"},{"key":"key20190724132637972_ref1-bib94","volume-title":"Stockley\u2019s Drug Interactions","author":"Baxter","year":"2017"},{"key":"key20190724132637972_ref1-bib95","volume-title":"Introductory Guide MedDRA Version 13.1","author":"MedDRA MSSO","year":"2010"},{"key":"key20190724132637972_ref1-bib96","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1164\/rccm.201712-2493OC","article-title":"Determinants of response to roflumilast in severe COPD: pooled analysis of two randomized trials","volume":"198","author":"Martinez","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"key20190724132637972_ref1-bib97","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1164\/arrd.1987.135.5.1069","article-title":"Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity, and quality of life","volume":"135","author":"Guyatt","year":"1987","journal-title":"Am Rev Respir Dis"},{"key":"key20190724132637972_ref1-bib98","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.4187\/respcare.02748","article-title":"Disease management programs for patients with COPD in Germany: a longitudinal evaluation of routinely collected patient records","volume":"59","author":"Mehring","year":"2014","journal-title":"Respir Care"},{"key":"key20190724132637972_ref1-bib99","first-page":"OC10","article-title":"The study of efficacy, tolerability and safety of theophylline given along with formoterol plus budesonide in COPD","volume":"9","author":"Subramanian","year":"2015","journal-title":"Journal of Clinical and Diagnostic Research"},{"key":"key20190724132637972_ref1-bib100","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/j.rmed.2012.09.006","article-title":"Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium","volume":"106","author":"Hettle","year":"2012","journal-title":"Respir Med"},{"key":"key20190724132637972_ref1-bib101","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1183\/09031936.00099306","article-title":"Outcomes for COPD pharmacological trials: from lung function to biomarkers","volume":"31","author":"Cazzola","year":"2008","journal-title":"Eur Respir J"},{"key":"key20190724132637972_ref1-bib102","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","article-title":"Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"key":"key20190724132637972_ref1-bib103","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0140-6736(14)62410-7","article-title":"Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial","volume":"385","author":"Martinez","year":"2015","journal-title":"Lancet"},{"key":"key20190724132637972_ref1-bib104","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJMoa1608033","article-title":"Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice","volume":"375","author":"Vestbo","year":"2016","journal-title":"N Engl J Med"},{"key":"key20190724132637972_ref1-bib105","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1164\/ajrccm.164.2.2006043","article-title":"Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma","volume":"164","author":"Lim","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"key20190724132637972_ref1-bib106","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/S0140-6736(94)90127-9","article-title":"Anti-inflammatory effects of low-dose oral theophylline in atopic asthma","volume":"343","author":"Sullivan","year":"1994","journal-title":"Lancet"},{"key":"key20190724132637972_ref1-bib107","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.rmed.2004.02.020","article-title":"A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD","volume":"98","author":"Ohta","year":"2004","journal-title":"Respir Med"},{"key":"key20190724132637972_ref1-bib108","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1365-2125.1980.tb01726.x","article-title":"Theophylline kinetics in relation to age: the importance of smoking","volume":"10","author":"Cusack","year":"1980","journal-title":"Br J Clin Pharmacol"},{"key":"key20190724132637972_ref1-bib109","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1136\/thx.2005.041806","article-title":"COPD exacerbations .1: epidemiology","volume":"61","author":"Donaldson","year":"2006","journal-title":"Thorax"},{"key":"key20190724132637972_ref1-bib110","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1378\/chest.07-1692","article-title":"Reported and unreported exacerbations of COPD: analysis by diary cards","volume":"133","author":"Vijayasaratha","year":"2008","journal-title":"Chest"},{"key":"key20190724132637972_ref1-bib111","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.rmed.2007.01.012","article-title":"Effects of an integrated care intervention on risk factors of COPD readmission","volume":"101","author":"Garcia-Aymerich","year":"2007","journal-title":"Respir Med"},{"key":"key20190724132637972_ref1-bib112","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1183\/09031936.00035909","article-title":"Predictive accuracy of patient-reported exacerbation frequency in COPD","volume":"37","author":"Quint","year":"2011","journal-title":"Eur Respir J"},{"key":"key20190724132637972_ref1-bib113","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2147\/COPD.S4257","article-title":"Geographic differences in clinical characteristics and management of COPD: the EPOCA study","volume":"3","author":"Miravitlles","year":"2008","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"key20190724132637972_ref1-bib114","doi-asserted-by":"publisher","first-page":"79","DOI":"10.4104\/pcrj.2013.00014","article-title":"Guideline-based COPD management in a resource-limited setting \u2013 physicians\u2019 understanding, adherence and barriers: a cross-sectional survey of internal and family medicine hospital-based physicians in Nigeria","volume":"22","author":"Desalu","year":"2013","journal-title":"Prim Care Respir J"},{"key":"key20190724132637972_ref1-bib115","first-page":"206","article-title":"Patient\u2019s perspective of chronic obstructive pulmonary disease in Yanqing county of Beijing","volume":"31","author":"Shen","year":"2008","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"key20190724132637972_ref1-bib116","first-page":"199","article-title":"A study to monitor adverse drug reactions in patients of chronic obstructive pulmonary disease: focus on theophylline","volume":"50","author":"Tyagi","year":"2008","journal-title":"Indian J Chest Dis Allied Sci"},{"key":"key20190724132637972_ref1-bib117","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/j.1440-1843.2006.00897.x","article-title":"Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year","volume":"11","author":"Zhou","year":"2006","journal-title":"Respirology"},{"key":"key20190724132637972_ref1-bib118","volume-title":"Theophylline and Steroids in Chronic Obstructive Pulmonary Disease (COPD) Study (TASCS)","author":"Berend","year":"2017"},{"key":"key20190724132637972_ref1-bib119","first-page":"A7444","article-title":"Theophylline and systemic corticosteroids in COPD: the TASCS trial","volume":"199","author":"Jenkins","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"key20190724132637972_ref1-bib120","volume-title":"BICS","author":"University of Aberdeen"},{"key":"key20190724132637972_ref1-bib121","doi-asserted-by":"publisher","first-page":"CD012748","DOI":"10.1002\/14651858.CD012748","article-title":"Oral xanthine derivatives (theophylline and doxofylline) for patients with stable chronic obstructive pulmonary disease (COPD)","volume":"8","author":"Garc\u00eda Morales","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"key20190724132637972_ref1-bib122","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/clpt.1980.212","article-title":"Theophylline clearance: effect of marked obesity","volume":"28","author":"Blouin","year":"1980","journal-title":"Clin Pharmacol Ther"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta23370\/hta23370.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2009520","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta23370\/hta23370.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2029709","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:55:43Z","timestamp":1692114943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta23370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":122,"journal-issue":{"issue":"37","published-online":{"date-parts":[[2019,7]]}},"alternative-id":["10.3310\/hta23370"],"URL":"https:\/\/doi.org\/10.3310\/hta23370","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"}]}}